Natures Sunshine Products Inc NATR
We take great care to ensure that the data presented and summarized in this overview for NATURES SUNSHINE PRODUCTS INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in NATR
Top Purchases
Top Sells
About NATR
Nature's Sunshine Products, Inc., a natural health and wellness company, primarily manufactures and sells nutritional and personal care products in Asia, Europe, North America, Latin America, and internationally. It offers general health products related to blood sugar support, bone health, cellular health, cognitive function, joint health, mood, sexual health, sleep, sports and energy, and vision. The company also provides immunity, cardiovascular, and digestive products; and personal care products, such as oils and lotions, aloe vera gels, herbal shampoos, herbal skin treatment, toothpaste, and skin cleansers, as well as weight management products. It offers its products under the Nature's Sunshine and Synergy WorldWide brands through a sales force of independent consultants. The company was founded in 1972 and is headquartered in Lehi, Utah.
Insider Transactions at NATR
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 15
2024
|
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
2,300
-3.46%
|
$29,900
$13.02 P/Share
|
|
Oct 14
2024
|
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
1,300
-1.92%
|
$16,900
$13.12 P/Share
|
|
Oct 11
2024
|
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
1,580
-2.28%
|
$20,540
$13.37 P/Share
|
|
Oct 10
2024
|
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
3,000
-4.15%
|
$39,000
$13.39 P/Share
|
|
Oct 09
2024
|
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
1,816
-2.45%
|
$23,608
$13.36 P/Share
|
|
Oct 08
2024
|
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
1,800
-2.37%
|
$23,400
$13.13 P/Share
|
|
Oct 01
2024
|
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
1,399
-1.81%
|
$18,187
$13.54 P/Share
|
|
Sep 26
2024
|
Kevin Gregory Fuller Global Chief Marketing Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,070
+50.0%
|
-
|
|
Sep 06
2024
|
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. > 10% Shareholder |
BUY
Other acquisition or disposition
|
Indirect |
2,968
+3.69%
|
-
|
|
Sep 06
2024
|
Jonathan David Lanoy SVP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,653
-5.31%
|
$34,489
$13.05 P/Share
|
|
Jul 21
2024
|
Tracee Comstock VP, Human Resources |
SELL
Payment of exercise price or tax liability
|
Direct |
1,236
-2.1%
|
$18,540
$15.55 P/Share
|
|
Jul 21
2024
|
Nathan G Brower EVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
1,376
-2.74%
|
$20,640
$15.55 P/Share
|
|
Jul 21
2024
|
Daniel C Norman EVP & President, Asia |
SELL
Payment of exercise price or tax liability
|
Direct |
1,553
-2.41%
|
$23,295
$15.55 P/Share
|
|
Jul 21
2024
|
Bryant J Yates EVP & President, Europe |
SELL
Payment of exercise price or tax liability
|
Direct |
1,553
-1.57%
|
$23,295
$15.55 P/Share
|
|
Jul 21
2024
|
Jonathan David Lanoy SVP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
341
-0.68%
|
$5,115
$15.55 P/Share
|
|
Jul 21
2024
|
Terrence Moorehead Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,313
-1.8%
|
$139,695
$15.55 P/Share
|
|
Jul 21
2024
|
Martin A. Gonzalez EVP, Global Supply Chain |
SELL
Payment of exercise price or tax liability
|
Direct |
3,787
-6.25%
|
$56,805
$15.55 P/Share
|
|
Jun 26
2024
|
Kevin R. Herbert EVP & President, North America |
SELL
Payment of exercise price or tax liability
|
Direct |
2,406
-7.03%
|
$36,090
$15.0 P/Share
|
|
Jun 06
2024
|
Bryant J Yates EVP & President, Europe |
SELL
Open market or private sale
|
Direct |
3,068
-3.01%
|
$46,020
$15.3 P/Share
|
|
May 06
2024
|
John Christopher Teets Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,236
+8.65%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 186K shares |
|---|---|
| Other acquisition or disposition | 2.97K shares |
| Payment of exercise price or tax liability | 59.6K shares |
|---|---|
| Open market or private sale | 35.3K shares |